Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals

This publication has 33 references indexed in Scilit:

• HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine, a Novel Marker of Endothelial Dysfunction
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
• HIV Infection, Inflammation, Immunosenescence, and Aging
  Annual Review of Medicine, 2011
• Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
• Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers
  Pharmacological Research, 2009
• Asymmetric Dimethylarginine Reference Intervals Determined with Liquid Chromatography–Tandem Mass Spectrometry: Results from the Framingham Offspring Cohort
  Clinical Chemistry, 2009
• Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community
  Circulation, 2009
• Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy
  JACC, 2008
• Protein methylation is required to maintain optimal HIV-1 infectivity
  Retrovirology, 2006
• Asymmetrical Dimethylarginine
  Circulation, 2004
• Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction
  Circulation, 1998